Assenagon Asset Management S.A. Takes Position in Halozyme Therapeutics, Inc. $HALO

Assenagon Asset Management S.A. acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 72,085 shares of the biopharmaceutical company’s stock, valued at approximately $4,851,000. Assenagon Asset Management S.A. owned 0.06% of Halozyme Therapeutics as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of HALO. DLD Asset Management LP increased its stake in shares of Halozyme Therapeutics by 20.0% in the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after purchasing an additional 5,000,000 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in shares of Halozyme Therapeutics by 127.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock valued at $132,192,000 after buying an additional 1,425,674 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Halozyme Therapeutics by 294.1% during the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock worth $106,395,000 after buying an additional 1,082,638 shares during the period. Voloridge Investment Management LLC bought a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $77,587,000. Finally, Qube Research & Technologies Ltd bought a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $51,295,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 2.6%

Shares of NASDAQ:HALO opened at $61.63 on Friday. The firm has a 50 day simple moving average of $70.59 and a 200 day simple moving average of $69.76. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22. The company has a debt-to-equity ratio of 43.89, a quick ratio of 3.66 and a current ratio of 4.66. The company has a market cap of $7.30 billion, a PE ratio of 24.75, a price-to-earnings-growth ratio of 0.25 and a beta of 0.98.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). The firm had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The company’s revenue for the quarter was up 51.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.26 earnings per share. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HALO. The Goldman Sachs Group reissued a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. Wells Fargo & Company raised their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $78.56.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $70.21, for a total transaction of $702,100.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $53,905,833.80. The trade was a 1.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at $2,818,640.75. This represents a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 90,857 shares of company stock valued at $6,500,287. Corporate insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.